A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Carcinoma, Hepatocellular

Treatments: Drug: Brivanib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00437424

CA182-015

Details and patient eligibility

About

The primary purpose of this protocol is to determine the effect of BMS-582664 on patients with hepatocellular carcinoma with varying levels of hepatic impairment

Enrollment: 24 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Subjects with a biopsy proven advanced solid tumor
• Subjects with a biopsy proven diagnosis of hepatocellular carcinoma conforming to child pugh classifications A, B, or C

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

24 participants in 1 patient group

1

Experimental group

Treatment:

Drug: Brivanib